Radiology AI Directory

FDA-cleared profile

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Parallel triage notification of suspected aortic dissection on contrast CT chest/abdomen; compressed previews are not diagnostic.

Acute triage and notification
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.

Product overview

Start with the essentials

Authorized purpose: Parallel triage notification of suspected aortic dissection on contrast CT chest/abdomen; compressed previews are not diagnostic.

Overview status: Source-reviewed overview

Clinical takeaway

Clinical role: Parallel triage notification of suspected aortic dissection on contrast CT chest/abdomen; compressed previews are not diagnostic.

Evidence takeaway

Evidence from the reviewed source record: FDA retrospective blinded multicenter performance testing used 509 contrast CT chest/abdomen cases from five U.S. clinical sites, with ground truth from three senior board-certified radiologists. Primary sensitivity was 92.7% (95% CI 88.2%-95.8%) and specificity was 92.8% (95% CI 89.2%-95.4%) against an 80% performance goal. Secondary mean time-to-notification for true-positive subject cases was 10.7 seconds (95% CI 10.5-10.9), compared with 38.0 seconds for the predicate.

Clinical details

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Parallel triage notification of suspected aortic dissection on contrast CT chest/abdomen; compressed previews are not diagnostic.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Hospital networks and appropriately trained medical specialists
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Care setting and population
Hospital networks and clinical workflow triage
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Parallel worklist triage and notification support; the original PACS images remain the basis for diagnostic interpretation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Filtered DICOM contrast CT chest, abdomen, or chest/abdomen exams, including CTA and CT with contrast, from adults or transitional adolescents aged 18 and older; slice thickness 0.5-5.0 mm and adequate field of view are required.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Output and human action
A priority flag and pop-up notification for suspected aortic dissection in a standalone desktop/image-review workflow, with an unannotated, compressed, low-quality grayscale preview for informational prioritization; the original medical image is not altered.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Not a diagnostic device and preview images are not for diagnosis beyond notification. Full original images in PACS must be reviewed with other patient information and professional judgment. Scope is contrast CT chest/abdomen in patients aged 18 and older, slice thickness 0.5-5.0 mm, excluding inadequate field of view.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251406
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Chest and abdomen; suspected aortic dissection
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-05-30
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
A Linux-based server in a cloud environment receives filtered DICOM images, processes series chronologically, and transfers algorithm output to desktop image-review software with pop-up notification and worklist prioritization; diagnostic assessment occurs on original PACS images. Specific local interfaces are not established.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Deployment and data flow
On-cloud
  • Public source
  • Exact FDA submission
  • Checked 2026-08-13

Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.

Security and privacy
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-08

Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

Training and support
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-08

Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

Monitoring and change control
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-08

Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for BriefCase-Triage; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission ยท checked 2026-09-08
Source

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA retrospective blinded multicenter performance testing used 509 contrast CT chest/abdomen cases from five U.S. clinical sites, with ground truth from three senior board-certified radiologists. Primary sensitivity was 92.7% (95% CI 88.2%-95.8%) and specificity was 92.8% (95% CI 89.2%-95.4%) against an 80% performance goal. Secondary mean time-to-notification for true-positive subject cases was 10.7 seconds (95% CI 10.5-10.9), compared with 38.0 seconds for the predicate.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
92.7% (95% CI: 88.2%, 95.8%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
92.8% (95% CI: 89.2%, 95.4%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

BriefCase-Aortic Dissection Triage regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K251406
  • Samplen=509
  • Sites5
  • IndependenceIndependence not established

K251406

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Source

Costs and setup

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Vendor documentation pending
  • Vendor confirmation
  • Exact FDA submission
  • Checked 2026-09-08

No public price or quote for the exact K251406 configuration was established in this review.

Reimbursement and coding
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-08

No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K251406. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Sources & history

How this profile was documented

Open the ledger for source dates, scope, and research-record updates.

View source ledger and history

Source ledger

  1. FDA K251406: BriefCase-Triage

    U.S. Food and Drug Administration - Published 2025-05-30 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. BriefCase-Aortic Dissection Triage model card (K251406)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K251406

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K251406 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260729

Vascular Assist Occlusion Triage (VAOT) (v1.0)

GuideAI Health

Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening,...

Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Decision
2026-06-18
Detection and CADeAcute triage and notification
FDA-cleared K261317

BriefCase-Triage

Aidoc Medical, Ltd.

Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.

Modality
CT/CTA
Anatomy
Head/Brain
Decision
2026-05-14
Acute triage and notification
FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during...

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24
Stroke and ICH triageAcute triage and notification